Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
7.99
+0.05 (0.63%)
At close: Mar 6, 2026, 4:00 PM EST
8.55
+0.56 (7.01%)
After-hours: Mar 6, 2026, 7:26 PM EST
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-$960,907
Market Cap
481.69M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Lyell Immunopharma | 300 |
| Rocket Pharmaceuticals | 202 |
| Century Therapeutics | 150 |
| Kyverna Therapeutics | 129 |
| Lexeo Therapeutics | 61 |
| Altimmune | 59 |
| Zevra Therapeutics | 59 |
EPRX News
- 15 days ago - Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 16 days ago - Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 16 days ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire